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Neurodegenerative diseaseNeurodegenerative protein misfolding diseases, including prionopathies, share the common feature of accu-
mulating speciﬁc misfolded proteins, with a molecular mechanism closely related. Misfolded prion protein
(PrP) generates soluble oligomers that, in turn, aggregate into amyloid ﬁbers. Preventing the formation of
these entities, crucially associated with the neurotoxic and/or infectious properties of the resulting abnormal
PrP, represents an attractive therapeutic strategy to ameliorate prionopathies. We focused our attention into
methylene blue (MB), a well-characterized drug, which is under study against Alzheimer's disease and other
neurodegenerative disorders. Here, we have undertaken an in vitro study on the effects of MB on oligomer-
ization and ﬁbrillization of human, ovine and murine PrP. We demonstrated that MB affects the kinetics of
PrP oligomerization and reduces the amount of oligomer of about 30%, in a pH-dependent manner, by
using SLS and DSC methodologies. Moreover, TEM images showed that MB completely suppresses ﬁber for-
mation at a PrP:MB molar ratio of 1:2. Finally, NMR revealed a direct interaction between PrP and MB, which
was mapped on a surface cleft including a ﬁbrillogenic region of the protein. Our results allowed to surmise a
mechanism of action in which the MB binding to PrP surface markedly interferes with the pathway towards
oligomers and ﬁbres. Therefore MB could be considered as a general anti-aggregation compound, acting
against proteinopathies.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Neurodegenerative disorders such as Alzheimer's (AD), Parkinson's
and Huntington diseases, frontotemporal dementia and prion diseases
are included in the general family of protein misfolding pathologies.
These diseases show substantial overlap in their pathologicmechanisms
[1,2], with their main common characteristic being oligomer formation
followed by ﬁbrillar arrangement and deposition of misfolded proteins
in the brain [3,4].; wt-OvPrP, ovine recombinant
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l rights reserved.In particular, prion diseases are a family of rare but all fatal patholo-
gies, which affect humans, e.g. the Creutzfeldt–Jakob disease, and
various animal species, e.g. scrapie in sheep and goat, and bovine
spongiform encephalopathies in cattle. It is commonly accepted that
these diseases are caused by a conformational change of the cellular
prion protein (PrPC), which is rich in α-helix, to its β-sheet-rich
insoluble conformer, called scrapie PrP (PrPSc) [5]. How this con-
formational transition occurs is not yet clearly elucidated, despite
the plethora of studies [5–7]. All proposed mechanisms to describe
the conversion of PrPC into PrPSc suggest a multi-step process including
an oligomerization/polymerization step [7,8]. Based on the assumption
that one or more of the different conformational PrP states involved
(i.e. oligomers, proto-ﬁbrils, amyloidﬁbrils) correspond to the infectious
and/or toxic entity, various approaches aimed at targeting such abnor-
mal species are currently explored for therapeutic interventions.
Treating prion diseases remains a challenge for the scientiﬁc and
medical community. Although a large number of anti-prion agents
have been identiﬁed, none represents an efﬁcient cure. For pragmatic
reasons, and since the basic molecular mechanisms in protein
misfolding disorders are closely related, it seems reasonable to sur-
mise that some compounds, with anti-aggregation potency in various
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tive for prion diseases. Accordingly, we addressed our quest for new
anti-prion agents to compounds that are well characterized with
respect to their drug-like qualities. We focused on methylene blue
(MB) which has been commonly used for the treatment of several
medical conditions for at least 120 years [9] and currently being
tested in phase II clinical trials in AD [10].
MB is a water-soluble dye, belonging to the phenothiazine class.
This compound is approved by the Food and Drug Administration
for oral or i.v. administration for several pathologies. From a toxico-
logical point of view, MB is known to be scarcely toxic [10] and
more important, MB is able to pass the blood–brain barrier [11,12];
hence, it is suitable to reach neuronal targets.
MB has recently attracted increasing attention, because it has been
shown to slow down the progression of the AD patients with a net
improvement of cognitive function [10]. Nevertheless, its mechanism
of action remains unclear. At a molecular level, MB was found to
interfere, in vitro, with the aggregation of the Aβ42 [13], Aβ40 peptides
and tau proteins [14]. In addition, MB is able to antagonize other
amyloidogenic proteins; indeed, MB can modulate the polyglutamine
degradation, in a manner dependent on hsp70/hsp90 chaperone ma-
chinery [15], and impairs thedeposition of the TARDNA-bindingprotein
(TDP-43) in a cell culture model over-expressing a TDP-43 variant [16].
Although these ﬁndings support the notion that MB displays
anti-aggregating properties, the possibility of an interaction between
PrP and MB has not yet been explored. An important study focused on
phenothiazine structure–activity relationships and conducted in neu-
roblastoma ScN2a prion infected cells showed that MB was cytotoxic
for ScN2a cells and not able to inhibit the PrPSc formation [17]. How-
ever, its action could not be reliably examined because of its toxicity
toward these cells. On the other hand, in a recent study, red cells
suspended in MB treated plasma were prepared for neonatal ex-
change transfusion [18].
In this scenario, the scarce knowledge of MB action on prion protein,
with respect to other amyloidogenic proteins, prompted us to study the
effects of this compound on the PrP aggregation process, by using an en-
semble of biophysical methodologies. We report a direct interaction be-
tween MB and PrP, involving mainly the C-terminus of helix H2 and a
small region around helix H1, that were shown to possess high propen-
sity to aggregation [19]. By dissecting the action of MB along the poly-
merization reaction from monomers to ﬁbrils, we demonstrated the
effectiveness of this compound to antagonize both PrP oligomerization
and ﬁbrillization, by slowing down the formation of PrP oligomers, re-
ducing their amount and completely suppressing the formation ofﬁbers.
Collectively, these results allow us to surmise a mechanism of action of
MB that blocks the PrP conversion process.
2. Materials and methods
2.1. Materials
MB and Thioﬂavin T (ThT), at a purity≥95%, were purchased from
Sigma Aldrich. MB was dissolved in the same buffer used for the pro-
tein, depending on the experiments (see below). The stock solutions
were ﬁltered with a 0.2-mm ﬁlter, kept at 4 °C and made freshly for
each independent experiment.
2.2. Monomeric and oligomeric protein production
The full-length PrP from sheep OvPrP (A136 R154 Q171 variant), the
truncated form ΔOvPrP (103–234), the full-length mouse PrP (MoPrP)
and the full-length human PrP (HuPrP) were expressed in Escherichia
coli and puriﬁed as previously described [20]. All the mutants from
sheep, OvPrP_H190A, OvPrP_H190KI208M were obtained by introduc-
ing the respectivemutations into the ARQ gene cloned in a pET22bC vec-
tor by using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA).Different buffers were used to desalt the protein on a HiPrep
desalting column using an AKTA FPLC chromatography equipment
(GE Healthcare): sodium citrate 20 mM, pH 3.4; sodium acetate
20 mM, pH 4.6; MOPS 20 mM, pH 7.0. Final protein concentration
was measured by optical density at 280 nm using an extinction coef-
ﬁcient of 58718 M−1 cm2 for wt-OvPrP, wt-MoPrP and wt-HuPrP and
all the mutants and an extinction coefﬁcient of 18005 M−1 cm2 for
ΔOvPrP, deduced from the amino acid sequence.
2.3. Size exclusion chromatography (SEC)
The oligomerization pathway of the mutant OvPrP_ H190KI208M
was analyzed by SEC using a TSK 4000SW gel-ﬁltration column
(60×0.78 cm), in sodium citrate 20 mM, pH 3.4, at 20 °C. Several
PrP solutions, at the same concentration, 40 μM, were heated at
50 °C for incubation times ranging from 0 to 90 min, in a Perkin
Elmer GenAmp2400 thermocycler.
The formation of the O1 and O3 oligomers was obtained by
heating a solution of wt-OvPrP and wt-MoPrP (100 μM), in sodium
citrate 20 mM pH 3.4, at 60 °C for 12 h and 50 °C for 8 min, respec-
tively. Homogeneous fractions of each oligomer were collected.
2.4. Static light-scattering (SLS)
SLS kinetics experiments were performed on a homemade device
with four lasers (407, 473, 533, and 633 nm) using a 2 mm cuvette. The
oligomerization of wt-OvPrP, wt-MoPrP and the mutants OvPrP_H190A
and OvPrP_H190KI208M was monitored in the absence and presence of
MB at 50 °C and in sodium citrate 20 mM, pH 3.4 or MOPS 20 mM, pH
7.0. The concentration of protein samples was in the range 30–50 μM,
and several PrP:MBmolar ratios were analyzed. To estimate the percent-
age decrease of the SLS intensity in the presence of MB with respect to
that one without MB, the SLS values, after 60 min, were considered for
each curve.
For depolymerization experiments, O1 and O3 oligomers were incu-
bated in the SLS device in the absence and presence of MB at 75 and
55 °C, respectively. The concentration of oligomers used was 8 μM and
the depolymerization was performed using a oligomer:MB molar ratio
of 1:4. Signal processingwas achieved by a homemadeMatLab program.
2.5. Differential scanning calorimetry (DSC)
DSC thermograms were obtained by a MicroCal DSC instrument
with cell volumes of 0.5 mL, at a scan rate of 60 and 90 °C/h. All the
experiments were performed with full-length wt-OvPrP at 50 μM,
using three different pH conditions: sodium citrate 20 mM, pH 3.4;
sodium acetate 15 mM, pH 4.6 and MOPS 20 mM, pH 7.0. For each
condition, at least two thermograms were recorded with and without
MB, at PrP:MB molar ratio of 1:4. DSC thermograms were analyzed
with ORIGINLab software. Deconvolution of DSC curves obtained at
pH 7.0 was achieved by a homemade MatLab program applying the
Lumry–Eyring model for irreversible processes [21]. To estimate the
percentage of oligomers formed in the absence and presence of MB,
we calculated the area of the deconvoluted peaks corresponding to
the second transition.
2.6. Nuclear magnetic resonance (NMR)
MB titrations were followed by recording 1H-15N HSQC NMR
spectra of 0.2 mM samples of the 15N-labeled ΔOvPrP in sodium ace-
tate 20 mM, pH 4.6 and MOPS 5 mM, pH 7.0, at 25 °C on a Varian
600 MHz spectrometer. The water signal was suppressed by the
WATERGATE pulse sequence. Additions of MB from a stock solution
were done to reach the ﬁnal PrP:MB molar ratios of 1:1, 1:2, 1:5
and 1:10.
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The kinetics of ﬁbril formation was monitored using a ThT-binding
assay. Solvents and solutions were ﬁltered using 0.02-μm ﬁlters prior
usage. Lyophilized wt-HuPrP and wt-OvPrP were dissolved in MES
50 mM, pH 6.0. MB was dissolved in water to a ﬁnal concentration
of 22–220 μM. The ﬁbrillization reaction was started diluting the
PrP stock solution to a ﬁnal concentration of 22 μM in GdnHCl 2.0 M
and MES 0.5 mM, pH 6.0. A control sample without MB and several
samples, at different PrP:MB molar ratios, were prepared and imme-
diately incubated at 37 °C. During incubation, aliquots of the solu-
tions were collected at regular time intervals and diluted in sodium
acetate 10 mM, pH 5.0 to a ﬁnal PrP concentration of 0.3 μM. Then,
ThT was added to a ﬁnal concentration of 10 μM. For each sample,
emission spectra were recorded using a Jasco 6200 spectroﬂuorime-
ter with a 2 mm×10 mm optical path-length cuvette and an excita-
tion wavelength of 445 nm. Both excitation and emission slits were
5 nm. Spectra were averaged and the ﬂuorescence intensity at emission
maximum (482 nm) was determined. To evaluate if MB could interfere
with the ThT emission, ﬂuorescence spectra of the solutions containing
alternatively only ThT and both ThT andMBwere recorded, at themax-
imum concentration used for the samples PrP-MB. The emission of ThT
was the same with and without MB.
Fibril morphology was analyzed by TEM using a Zeiss EM902
(80 kV) microscope. Brieﬂy, 10 μL of the protein samples was adsorbed
onto carbon-coated Formvar grids (Agar Scientiﬁc). Then, each grid was
washed three times with water, stained with 2% uranyl acetate and ﬁ-
nally air-dried.3. Results
3.1. MB directly interacts with the ground state of PrP
To explore the interaction of MB with the native monomeric
folded PrP, we carried out NMR experiments at both pH 4.6 and 7.0.
Titration of 15N-labeled ΔOvPrP (ARQ variant) with MB at pH 4.6
followed by 15N-HSQC spectra did not result in variations either in
the chemical shifts or in the peak intensity up to a PrP:MB molar
ratio of 1:10 (data not shown). This result was conﬁrmed by DSC ex-
periments (Supplemental Fig. S1) performed on wt-OvPrP at pH 4.6,
which showed no variation of the melting temperature in the
presence of MB, suggesting that MB does not have any stabilizing or
destabilizing effect on the native PrP structure.
Contrarily, NMR titrations at pH 7.0 showed small but clear chem-
ical shift perturbations of up to nine resonances, namely N146, N156,
Y158, Y160, K188, T191, two of the T193-196multi-threonine stretch,
presumably T194 and T195 and Q215 (Fig. 1A). Identiﬁcation of these
peaks allowed us to map the interaction in a quite extended cleft on
the protein surface (1024 Å3), which would be able to host MB. The
cleft is lined by about 20 residues coming from the region around
the helix H1 and mainly from helix H2 and the N-terminal region of
helix H3 (Fig. 1B and C). Out of nine residues with chemical shifts
perturbed by the MB addition, six (N146, K188, T191, T194, T195
and Q215) fall in the cavity, and most of them are located on the
C-terminal tip of H2. The remaining residues out of cavity, Y158 and
Y160, lie in the loop connecting the helix H1 with the strand S2,
whereas N156 is the last H1 residue. The presence within the cavity
of a high number of ionizable residues (1 Arg, 2 Lys, 1 His and 5
Glu), which are able to affect the charge distribution, well explainsFig. 1. Mapping the surface of interaction with MB on native folded state of PrP. (A) Overla
(magenta) at a 1:5 PrP:MB molar ratio. Assignment of the resonances that shift more than
Binding surface cleft is shadowed. The cavity is lined by side chains of about 20 residues co
(H180, V183, N184, V187, K188, T191, V192, T194, T195), loop H2H3 in orange (E199) and h
are ionizable. The nine residues with resonances perturbed by MB addition are drawn as stic
structure element to which they belong. (C) The same representation as in (B), rotated bythe pH dependence of the cleft interaction with the positive MB
molecule (Fig. 1B and C). The effective charge of His180 and of ﬁve
Glu (approximate pKa 6 and 4, respectively) may play a key role
in attracting the positive MB molecule, within the explored pH in-
terval 4.6–7.0, being their pKa markedly inﬂuenced by the protein
environment.3.2. Methylene blue affects the kinetics of PrP oligomerization but not
depolymerization
In previous works, it was shown that PrP undergoes a polymeriza-
tion process upon thermal treatment, accompanied by the formation
of different population of oligomers, depending on the PrP species,
mutants and experimental conditions used [22–24]. In particular, at
pH 3.4, wt-OvPrP was shown to oligomerize into three different oligo-
mers, referred to as O1, O2 and O3, whereas wt-MoPrP and the variant
OvPrP_H190A give rise mostly to O3 and O1 oligomer, respectively
(see reaction scheme in Fig. 2A–C). In addition, we have designed and
produced a new mutant, OvPrP_H190KI208M, for which the corre-
sponding SEC proﬁle revealed the formation of O3 and ﬁbril-like assem-
blies, denoted P0 (Supplemental Fig. S2).
In order to evaluate if MB speciﬁcally interferes on a particular
PrP oligomerization pathway, we monitored the polymerization ki-
netics of wt-OvPrP, wt-MoPrP, and the variants OvPrP_H190A and
OvPrP_H190KI208M by SLS, in the presence and absence of MB, at
pH 3.4.
The SLS kinetic curves of all the PrP forms tested are shown in
Fig. 2A–D. In all cases, the kinetic proﬁles obtained in the presence
of MB differed from those obtained in the absence of MB, and the
higher the MB concentration was, the more the SLS intensity signal
decreased.
To obtain a quantitative estimation of the effect of MB, we evalu-
ated the SLS intensity decrease, which is indicative either of the olig-
omerization rate or of the decrease in the size of oligomers. The
results showed that, at pH 3.4, MB decreased the signal intensity of
wt-OvPrP, wt-MoPrP and OvPrP_H190A by about 10% at PrP:MB
molar ratio of 1:1, and by about 15% at a molar ratio of 1:3. For the
variant OvPrP_H190KI208M, the decrease of the SLS intensity signal
was about 15% and 30% compared to the protein alone, at PrP:MB
molar ratios of 1:1 and 1:3, respectively.
Taking into account that a direct interaction was observed by NMR
at pH 7.0, SLS kinetic experiments were performed also at this pH on
wt-OvPrP. Under this condition, the thermal treatment of the protein
gives rise to the formation of mainly O1 and P0 ﬁbril assemblies
(see reaction scheme in Fig. 2E), as previously described [24].
Interestingly, the SLS intensity decreased by about 40%, already
at PrP:MB molar ratio of 1:1, indicating a signiﬁcant greater effect
than at pH 3.4 (Fig. 2A). This general behavior clearly shows that
MB is able to slow down the PrP oligomerization rate, at both pH
3.4 and 7.0, even though the effect is much higher in neutral con-
ditions. All together, these experiments suggest that MB more efﬁ-
ciently affects the pathway of O1 and P0 assemblies which are
favorized at neutral pH. To determine if the decrease of oligomer
assemblies is due to their destabilization in the presence of MB,
we carried out SLS depolymerization experiments on the two
most representative oligomers O1 and O3, in the absence and pres-
ence of MB. The SLS iso-kinetics depolymerization curves, shown
in Fig. 3, indicated that MB does not affect the stability of oligomer
assemblies.y of 15N-HSQC spectrum of ΔOvPrP (black) with spectrum of ΔOvPrP titrated with MB
0.03 ppm is indicated. (B) Ribbon representation of ΔOvPrP structure (pdbcode 1y2s).
ming from loop S1H1 in blue (F144, N146), helix H1 in blue (E149), helix H2 in green
elix H3 in red (E203, I206, K207, E210, R211, E214, Q215). The nine residues underlined
k in magenta; the remaining ones are drawn as lines in the same color of the secondary
about 90°.
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Fig. 2. Polymerization kinetics of the various PrP forms tested, in the absence and presence of MB. Time evolution SLS curves, recorded monitoring the intensity signal at 407 nm
and at pH 3.4 of (A) wt-OvPrP, (B) wt-MoPrP, (C) OvPrP_H190A, (D) OvPrP_H190KI208M, and at pH 7.0 of (E) wt-OvPrP. The kinetic curves recorded in the absence of MB are
depicted in black, the kinetic curves recorded at a PrP:MB molar ratio of 1:1 in red, and at PrP:MB molar ratio of 1:3 in blue. The scheme of the oligomerization reaction is also
shown in each panel.
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To evaluate the effects of MB on the unfolding/oligomerization pro-
cess of PrP, DSC thermograms of wt-OvPrP, at pH 3.4 and 7.0, were
recorded in the absence and presence of MB. The DSC thermograms, at
both pH, showed two endothermic peaks corresponding to two transi-
tions, in agreement with previous experiments [25,26]. These two
transitions were explained as a PrP unfolding/oligomerization process,
followed by a depolymerization process [25].In acidic conditions, the thermograms with and without MB are
very similar (Fig. 4A). The area of both peaks, as well as the transition
temperatures in the two thermograms are roughly comparable, being
a small area reduction detected only for the second peak, in the pres-
ence of MB. This ﬁnding indicates that, at pH 3.4, MB barely inﬂuences
either the unfolding/oligomerization or the depolymerization process
of PrP.
On the contrary, in neutral conditions, the thermogram of wt-OvPrP
with MB is markedly different compared to the one in the absence of
Fig. 3. Depolymerization kinetics of PrP oligomers. Time evolution SLS curves, recorded
monitoring the intensity signal at 407 nm, in the absence and presence of MB, at pH 3.4
of (A) O3 and (B) O1 oligomer. The kinetic curves recorded in the absence of MB are
depicted in blue, and the kinetic curves recorded at a PrP:MB molar ratio of 1:4 are
in red.
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(Fig. 4B). Since this area is proportional to the relative amount of oligo-
mers formed during the ﬁrst transition, thermograms have been
deconvoluted to obtain a quantitative estimation of the oligomer reduc-
tion observed in the presence of MB. As shown in Fig. 4C, deconvolution
of the ﬁrst peaks, obtained with and without MB, shows no signiﬁcant
differences. Differently, deconvolution of the second peaks, relative to
the depolymerization of oligomers formed in the ﬁrst transition, reveals
meaningful differences in both the surface area and the transition
temperature. Indeed, in the presence of MB, the peak area is re-
duced by about 28%, indicating a signiﬁcant decrease of the oligo-
mer formation, and the transition temperature decreased by about
4 °C, in accordance with the Lumry–Eyring model, in which the
concentration of oligomers is directly proportional to the second
transition temperature [21,26].
These ﬁndings fully conﬁrm that MB signiﬁcantly interferes with
the PrP oligomer formation at physiologic pH, by reducing both the
oligomerization rate, as observed by SLS, and the amount of oligo-
mers formed along the oligomerization pathway.3.4. MB completely suppresses PrP ﬁbril formation
Finally, the action of MB on ﬁbril formation was also studied.
wt-HuPrP and wt-OvPrP ﬁbrils were generated at pH 6.0 in the
absence – as control – and in the presence of MB. The PrP ﬁbril forma-
tion was monitored using ThT-binding assay. In Fig. 5A and B the
kinetic curves of the wt-HuPrP and wt-OvPrP ﬁbril formation are
shown, at different PrP:MB molar ratios. For both PrP species, in the
absence of MB, the ThT signal intensity gradually rises with a sigmoi-
dal shape, indicating the formation of PrP ﬁbrils. Differently, in the
presence of MB, within the range 1:0bPrP:MBb1:2, a longer lag
phase is observed, which increases in a dose-dependent manner
(see Supplemental Fig. S3A and B) and, at PrP:MB molar ratios equal
to or lesser than 1:2, the ﬁbril formation was completely inhibited.
A valuable conﬁrmation that the ﬁbril formation is suppressed by
MB was obtained by TEM images (Fig. 5C–F). For both wt-HuPrP and
wt-OvPrP, typical ﬁbrillar structures were observed in the absence of
MB (Fig. 5C and E). On the other hand, surveying the entire EM grid,
none or very little ﬁbrillar material was observed for samples incubat-
ed with MB at PrP:MBmolar ratios lesser than 1:2 (Fig. 5D and F). The
TEM images of the solutions at PrP:MB molar ratios higher than 1:2
conﬁrm the results obtained by ThT ﬂuorescence assays, showing
the formation of ﬁbrils, even if a little decrease on the ﬁbril amount
was detected (Supplemental Fig. S3C–F).
4. Discussion
A widely explored ﬁeld in prion diseases is the evaluation, primar-
ily in vitro, of compounds that can interfere with the PrPC→PrPSc con-
version, and be potentially used as drugs against these diseases.
Different drug discovery strategies have been reported [27–29], but
for many of these compounds, the clinical potentiality is unclear, be-
cause of pharmacological hurdles. For these reasons, we sought a
known molecule that could fulﬁll safety features required for drugs
delivery to humans and animals, and could actually be considered
for future in vivo applications. The pharmacokinetic and toxicological
properties of MB are well-known. More importantly, MB has been
shown to overpass the blood–brain barrier [11,12] and thus is suit-
able to target PrP in the brain. Previous data on the beneﬁcial effects
of MB for the treatment of neurodegeneration due to protein
misfolding and aggregation [9,10] suggest a general action of MB as
an anti-aggregation compound. As far as the prion is concerned, MB
was already investigated a decade ago [17]. In neuroblastoma ScN2a
prion infected cells, MB was shown to be cytotoxic for these cells
and not to impair the PrPSc formation. Anyhow, it should be noted
that its high toxicity for ScN2a cells might have not allowed to exam-
ine its effectiveness against PrPSc formation [17]. More recently,
positive data were obtained about MB treated prion-ﬁltered red
cells utilized for neonatal transfusion to reduce the risk of variant
Creutzfeldt–Jakob disease transmission [18]. Therefore, it would be
worthwhile to conduct further studies. In this work, we provide the
ﬁrst clear evidence of an effect of MB on PrP oligomer and ﬁber for-
mation pathways, in vitro, and a mechanism by which this occurs.
By dissecting the action of MB along each step of the PrP aggrega-
tion pathway, we demonstrated that MB (i) directly binds to a surface
cleft of native PrP, (ii) signiﬁcantly affects the oligomerization kinetic
rate of all the PrP forms used, (iii) limits the amount of oligomers
formed during the heat-induced unfolding/oligomerization process,
and (iv) completely suppresses ﬁbril formation.
Interestingly, a pH dependence of MB action, driven by the vari-
able charge distribution of the cleft on PrP surface, was systematically
observed in all NMR, SLS and DSC experiments, even though these
techniques measured distinct entities, under very different condi-
tions. At pH 3.4 and 50 °C, SLS analysis showed a lower effect of MB
on PrP oligomerization process with respect to neutral pH. On the
other hand, only at pH 7.0, DSC and NMR experiments showed a
Fig. 4. DSC thermograms of wt-OvPrP, in the absence (in red) and presence (in blue) of MB, at (A) pH 3.4 and (B) pH 7.0. (C) Deconvolution of the experimental DSC curves obtained
at pH 7.0. Continuous lines correspond to the experimental Cp data. Symbols represent the predicted Cp curves (in cyan without MB, in green with MB) of each transition peak in
which the global curves can be deconvoluted. The PrP:MB molar ratio was 1:4.
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heat-induced processes. NMR titration revealed a clear chemical shift
variation of 9 residues of the monomeric PrP at room temperature.
The major effects were then consistently observed at physiological
pH, indicating that MB is suitable to efﬁciently act in vivo. It is
worth noting that a greater inhibition effect was observed for the
oligomerization reaction generating ﬁber-like species, such as for
the double mutant. This suggests that MB may have an inhibitory
action directed toward ﬁbrillization, which was conﬁrmed by TEM
experiments that clearly indicated the complete inhibition of ﬁbril
formation, below a molar ratio PrP:MB of 1:2.
Our results well agree with literature data on other amyloidogenic
proteins from which it emerges that oligomerization and/or
ﬁbrillization are the steps affected by MB, even though its way of
action seems very variable [13–16]. Indeed, MB may have different
targets, and thus different modes of anti-aggregation action. For the
Aβ42 peptide Necula et al. [13] reported that MB inhibits the oligo-
merization through a stabilization of prenuclear Aβ42 assembly. In
their investigation of the effects on soluble oligomers of Aβ42 of MB
and other small aromatic molecules, Ladiwala et al. [30] highlighted
their action of remodeling mature protein aggregates by converting
soluble oligomers into off-pathway non toxic aggregates. Moreover,
MB has been shown to block the tau–tau binding interaction,
inhibiting tau ﬁlament formation in vitro, even though recent papers
argue for lack of MB effect on tau aggregation in vivo [14,31]. MB isalso able to inhibit ﬁbril formation of TDP-43 by binding dimers and
oligomers [16].
As far as PrP is concerned, it is worth underlining that our in vitro re-
sults do not contradict those obtained by Korth et al. [17], which were
obtained in highly different conditions, speciﬁcally in neuroblastoma
ScN2a cells infected by a given prion strain. The present study was
conducted in vitro using a variety of biophysical techniques. We believe
that our results can contribute to understand the action of MB on the
various steps on the route toward the ﬁber formation.
Thepotential anti-prion agents hitherto evaluated act through differ-
ent mechanisms. These compounds were shown to antagonize PrP con-
version by a direct interaction with the native PrP [32–34] or by acting
on the PrP species formed along the oligomerization/ﬁbrillization path-
way [29] or by sequestering the infectious self-propagating template
PrPSc [35]. Our results clearly indicate a direct interaction between MB
and the native monomeric folded PrP, at physiological pH, and rule out
a direct interaction with the oligomeric PrP forms. Speciﬁcally NMR ex-
periments showed that MB binds to an external cleft that contains resi-
dues belonging to the C-terminal tip of H2 helix (Fig. 1B). This part
together with the region around helix H1 are under-protected regions,
having quite a number of solvent exposed backbone H-bonds [19]. In-
deed, these H-bonds are not protected againstwater interaction. As a re-
sult, the regions embodying such H-bonds are structurally more labile,
and could act as aggregation loci, leading to ﬁbrillar polymerization
[19]. In this scenario, the binding of MB to the cleft of the protein may
Fig. 5. Inhibition of wt-HuPrP and wt-OvPrP ﬁbrillization mediated by MB. ThT ﬂuorescence measurements of ﬁbrillogenesis of (A) wt-HuPrP and (B) wt-OvPrP in the absence and
presence of several concentrations of MB. Results represent means±SD (n=3). TEM images of wt-HuPrP ﬁbrils formed (C) in the absence of MB (as control) and (D) in the pres-
ence of MB at a HuPrP:MB molar ratio of 1:5. TEM images of wt-OvPrP ﬁbrils formed (E) in the absence of MB (as control) and (F) in the presence of MB at a OvPrP:MBmolar ratio of
1:5. Scale bar: 0.5 μm.
27P. Cavaliere et al. / Biochimica et Biophysica Acta 1832 (2013) 20–28hamper the oligomer formation and hence blocks the pathway to ﬁber
formation. However, it is noteworthy that, although our results do not
show any direct interaction with the oligomeric PrP forms, they do not
rule out the hypothesis of an inference of MB on early intermediates
that precede the formation of oligomers.
To sum up, our work is the ﬁrst that shows the great potentiality of
MB as an anti-aggregation compound for prion conversion. The cleft ex-
posed to the solvent (Fig. 1B and C) that we ﬁnd hosting MB embodies
the C-terminal tip of H2 helix, a known structurally instable PrP region
that may favor partially unfolded structures with a resulting potential
for aggregation [19]. A drug such as MB, which well ﬁts into the cavity,
may then behave as an efﬁcient obstacle to aggregation. In particular,
the effectiveness of MB is endorsed in physiological conditions, antago-
nizing both oligomerization and ﬁbrillization processes. This is a highly
valuable feature ofMB because it interfereswith both PrP forms carrying
the toxicity and infectivity in prion diseases. Indeed, either soluble
oligomers or insoluble ﬁbrils were reported to be neurotoxic in vitro
and in vivo [36,37], whereas PrP ﬁbrils were also shown to be infectious
in vivo [38]. In conclusion, these results pave theway to the evaluation of
MB in in vivo studies and preclinical testing for prion diseases.
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